QMPSB is an arylsulfonamide-based
synthetic cannabinoid
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids (THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic ...
that has been sold as a
designer drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Des ...
.
QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full
agonist
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...
of the
CB1 receptor and
CB2 receptor with K
i values of 3 nM and 4 nM, respectively. Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB
2 receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004.
The quinolin-8-yl ester
motif of QMPSB led to the discovery of other designer cannabinoids such as
PB-22
PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ...
and
BB-22.
See also
*
2F-QMPSB
*
5F-PB-22
5F-PB-22 (5F-QUPIC or quinolin-8-yl 1-pentyfluoro-1''H''-indole-3-8-carboxylate) is a designer drug which acts as a cannabinoid agonist. The structure of 5F-PB-22 appears to have been designed with an understanding of structure–activity relati ...
*
FDU-PB-22
FDU-PB-22 is a derivative of JWH-018 that is presumed to be a potent agonist of the CB1 receptor, and has been sold online as a designer drug.
Pharmacology
FDU-PB-22 acts as a full agonist with a binding affinity of 1.19nM at CB1 and 2.43nM at ...
*
FUB-PB-22
FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.
Pharmacology
FUB-PB-22 acts as a full agonist with a binding affinity of 0.386nM at CB1 and ...
*
NM-2201
NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low n ...
*
O-2050
O-2050 is a drug that is a classical cannabinoid derivative, which acts as an antagonist for the CB1 receptor. This gives it an advantage in research over many commonly used cannabinoid antagonists, such as rimonabant, which at higher doses act ...
*
O-2113
O-2113 is a drug that is a classical cannabinoid derivative, which acts as a potent agonist for cannabinoid receptors, producing sedation, hypothermia and analgesia
Pain management is an aspect of medicine and health care involving relief ...
*
SDB-005
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline ...
References
Arylsulfonamides
Cannabinoids
Designer drugs
1-Piperidinyl compounds
Quinolines
{{cannabinoid-stub